Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 3/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21072118 | 1.00 | MEN1 (0.35) | MEN1MAPTKMT2APOLBALDH1A1 | |
| SCHEMBL2003186 | 0.89 | ESR1 (0.32) | ALDH1A1 | |
| SCHEMBL2873876 | 0.89 | ESR1 (0.32) | ALDH1A1 | |
| SCHEMBL16935673 | 0.86 | MEN1 (0.32) | MEN1MAPTKMT2APOLBALDH1A1 | |
| SCHEMBL20214001 | 0.81 | CHRNB2 (0.35) | — | |
| SCHEMBL1068167 | 0.79 | MEN1 (0.54) | MEN1MAPTKMT2AALDH1A1CA1 | |
| SCHEMBL1068169 | 0.79 | MEN1 (0.54) | MEN1MAPTKMT2AALDH1A1CA1 | |
| SCHEMBL21127524 | 0.78 | SMN1; SMN2 (0.39) | MEN1KMT2APOLBALDH1A1LMNA | |
| SCHEMBL2206284 | 0.77 | ALDH1A1 (0.33) | ALDH1A1LMNA | |
| SCHEMBL10599146 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188851-A1 | BROAD-SPECTRUM CARBAPENEMS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-06-24 | — | — | US | disclosed |
| EP-3802538-A1 | BROAD-SPECTRUM CARBAPENEMS | Venatorx Pharmaceuticals, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-112513043-A | Broad spectrum carbapenems | 维纳拓尔斯制药公司 | 2021-03-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188851-A1 | BROAD-SPECTRUM CARBAPENEMS | MGAM, ALPI, SI | MEN1 3883/4885MAPT 3803/4885KMT2A 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.